Excellence.
Partnership
-
Hao LiuFounder & Chairman
Hao Liu has over 20 years of experience in healthcare project investment and hospital operations management within China’s healthcare industry.
In 2014, he co-founded Haoyue Capital. He has completed over a hundred private financing and M&A restructuring projects across sectors including biopharmaceuticals, innovative
medical devices, IVD and life sciences, and healthcare services and smart medicine. Previously, he served as the Head of Healthcare at China Renaissance and Head of Investment Management in the Healthcare Department at Far East Horizon.
He holds a Master degree in Marketing Analysis with Distinction from Ghent University, Belgium.
-
Vincent DingManaging Partner & CEOVincent has over 20 years of experience in venture capital, mergers and acquisitions, and investment banking within China’s healthcare industry.
In 2014, he co-founded Haoyue Capital. He has led or deeply participated in more than 100 successful transactions, including private financings, M&A restructurings, and listed
company spin-offs. Representative deals include Asia Medical, ClinChoice, Yikun Biotech, the M&A restructurings of Reach Surgical and Yikang Pharmacy, and the spin-off financings of Conba and Salubris. Previously, he served as the Head of Healthcare Investments at
Legend Star, the angel investment arm of Legend Holdings.
He holds an EMBA from the China Europe International Business School (CEIBS) and
completed the Financial CEO Program at the PBC School of Finance, Tsinghua University.
-
Xiaokun WuPartnerXiaokun Wu brings over a decade of extensive experience in business development, M&A, and investment banking within China's healthcare sector.
Since joining Haoyue Capital in 2020, she has spearheaded dozens of marquee transactions covering private financing, M&A and carve-out transactions of listed companies with a cumulative value approaching RMB 10 billion. Her deal coverage spans frontier sectors including AI-driven healthcare, small nucleic acid therapeutics, cell and gene therapy, ADC, TCE, synthetic biology, and consumer health. Prior to joining the firm, she served at the China Pharmaceutical Industry Information Center (CPHIIC).
She holds a Master's degree from School of Life Sciences, Fudan University.
Ms. Wu holds a Master of Science in Life Sciences from Fudan University.
-
Yuhao QianPartnerEric brings nearly a decade of experience in investment, financing, and complex M&A transactions across the healthcare sector.
He joined Haoyue Capital in 2017, where he leads complex mergers & acquisitions,
restructurings, and strategic financing mandates. His transaction track record includes private placement advisory for ClinChoice, Sintai Medical, Liangyihui, Venous Medical, Broncus, and Youlin Pharma, as well as restructuring and M&A execution for GBI Health, a medical device CDMO platform, and multiple private hospital groups.
Eric holds a Bachelor of Science in Pharmacy from China Pharmaceutical University and a Master of Public Health from Yale University.



























